Immune checkpoint inhibitor–related myocarditis in a patient with hepatocellular carcinoma: a case report

1

Immune checkpoint inhibitors can cause myocarditis, a serious immune-related adverse event, in patients with hepatocellular carcinoma.
2

A 56-year-old man developed myocarditis after two cycles of the PD-1 inhibitor sintilimab, confirmed by cardiac magnetic resonance and endomyocardial biopsy.
3

Diagnosis of ICI-related myocarditis was supported by elevated cardiac biomarkers, ECG changes, and characteristic findings on cardiac imaging.
4

The patient was treated with high-dose corticosteroids, leading to significant clinical improvement and discharge on a tapering regimen.
5

This case highlights the need for early detection and management of ICI-related myocarditis to improve patient outcomes.

Frontiers In Cardiovascular Medicine

by Yuqiang Zhou, Zhiliang Zhang, Shasha Liu, Jiang Nan, Zhuoli Zhang, Zixian Chen
June 3, 2026

1